Ascendis Pharma A/S (NASDAQ:ASND) has received an average rating of "Buy" from the fourteen ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $185.75.
Several equities research analysts recently commented on ASND shares. Morgan Stanley boosted their target price on Ascendis Pharma A/S from $194.00 to $199.00 and gave the stock an "overweight" rating in a report on Friday, November 13th. Wedbush upped their price target on Ascendis Pharma A/S from $187.00 to $206.00 and gave the company an "outperform" rating in a report on Wednesday, September 30th. Zacks Investment Research downgraded shares of Ascendis Pharma A/S from a "hold" rating to a "strong sell" rating in a research note on Wednesday, January 13th. Berenberg Bank started coverage on shares of Ascendis Pharma A/S in a research note on Thursday, December 17th. They set a "buy" rating and a $216.00 target price on the stock. Finally, SVB Leerink boosted their price target on shares of Ascendis Pharma A/S from $173.00 to $191.00 and gave the company an "outperform" rating in a report on Thursday, November 12th.
A number of institutional investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA bought a new position in Ascendis Pharma A/S in the third quarter valued at approximately $102,740,000. Sei Investments Co. grew its position in shares of Ascendis Pharma A/S by 55.8% in the 3rd quarter. Sei Investments Co. now owns 234,774 shares of the biotechnology company's stock valued at $36,229,000 after acquiring an additional 84,122 shares during the period. Candriam Luxembourg S.C.A. grew its position in shares of Ascendis Pharma A/S by 41.6% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 269,079 shares of the biotechnology company's stock valued at $41,523,000 after acquiring an additional 79,000 shares during the period. Neuberger Berman Group LLC boosted its holdings in shares of Ascendis Pharma A/S by 78.2% during the 2nd quarter. Neuberger Berman Group LLC now owns 106,000 shares of the biotechnology company's stock worth $15,677,000 after buying an additional 46,500 shares during the period. Finally, New York State Common Retirement Fund boosted its holdings in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. New York State Common Retirement Fund now owns 287,666 shares of the biotechnology company's stock worth $44,393,000 after buying an additional 33,511 shares during the period.
Shares of NASDAQ ASND traded down $2.03 during midday trading on Wednesday, hitting $156.25. 6,577 shares of the company's stock were exchanged, compared to its average volume of 137,999. The stock's 50 day moving average price is $170.19 and its 200-day moving average price is $155.66. The firm has a market cap of $8.35 billion, a P/E ratio of -19.02 and a beta of 0.77. Ascendis Pharma A/S has a twelve month low of $92.00 and a twelve month high of $183.98.
Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Monday, November 16th. The biotechnology company reported ($2.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.57) by ($0.74). The business had revenue of $3.22 million for the quarter, compared to analyst estimates of $1.94 million. Ascendis Pharma A/S had a negative return on equity of 55.72% and a negative net margin of 4,042.79%. As a group, equities research analysts predict that Ascendis Pharma A/S will post -8.46 earnings per share for the current fiscal year.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia.
Recommended Story: What is a back-end load?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
12 Marijuana Stocks to Buy Now
There are now more than 50 publicly-traded companies operating in the cannabis industry. Most of these companies aren't directly growing and selling marijuana themselves, but they do stand to benefit greatly as more states legalize the sale and possession of marijuana. Some of these marijuana stocks are media companies. Others are privately studying the medical uses of marijuana. Yet others are providing tools and software for marijuana growers. As more cannabis companies file IPOs and enter the stock market, it will become increasingly difficult for investors to identify which marijuana stocks will truly benefit from the cannabis boom.
Our subscribers have begun digging through these companies, checking out their financials, business models and long-term growth prospects. They know that some "marijuana stocks" are just empty shell companies that deserve to be penny stocks, but they also recognize there are some legitimate and growing companies that truly stand to benefit from the green rush. As a group, they have added 10 different cannabis stocks to their watchlists and are actively investing in them. More than 1,400 MarketBeat subscribers are now following our top-trending cannabis company.
This slide show lists the 12 pot stocks that MarketBeat subscribers are have added to their watchlists and are actively monitoring.
View the "12 Marijuana Stocks to Buy Now".